← Back to Screener
Passage Bio, Inc. Common Stock (PASG)
Price$5.85
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-38.38%
Price vs S&P 500 (4W)11.12%
VGM Score32.63
Market Capitalization$18.51M
All Metrics
Book Value / Share (Quarterly)$3.66
P/TBV (Annual)0.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-9.55
Price vs S&P 500 (YTD)-62.04%
EPS (TTM)$-11.84
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-11.84
EPS (Annual)$-14.35
ROI (Annual)-242.72%
Cash / Share (Quarterly)$10.39
ROA (Last FY)-73.09%
EBITD / Share (TTM)$-12.70
ROE (5Y Avg)-113.18%
Cash Flow / Share (Annual)$-9.90
P/B Ratio1.57x
P/B Ratio (Quarterly)2.14x
Net Income / Employee (Annual)$-1,896,700
ROA (TTM)-59.78%
EPS Incl Extra (Annual)$-14.35
Current Ratio (Annual)2.07x
Quick Ratio (Quarterly)1.66x
3-Month Avg Trading Volume0.07M
52-Week Price Return-36.10%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.30
52-Week High$20.00
EPS Excl Extra (Annual)$-14.35
CapEx CAGR (5Y)-54.22%
26-Week Price Return-22.45%
Quick Ratio (Annual)2.01x
13-Week Price Return-33.37%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.73x
Enterprise Value$-14.83M
Book Value / Share Growth (5Y)-2.48%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$14.55
3-Month Return Std Dev141.87%
Net Income / Employee (TTM)$-1,569,800
ROE (Last FY)-242.72%
EPS Basic Excl Extra (Annual)$-14.35
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-11.84
ROI (TTM)-150.88%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.69
Price vs S&P 500 (52W)-64.31%
Year-to-Date Return-51.10%
5-Day Price Return10.43%
EPS Normalized (Annual)$-14.35
ROA (5Y Avg)-62.45%
Month-to-Date Return12.92%
Cash Flow / Share (TTM)$-1.98
EBITD / Share (Annual)$-15.31
ROI (5Y Avg)-113.18%
EPS Basic Excl Extra (TTM)$-11.84
P/TBV (Quarterly)0.27x
P/B Ratio (Annual)1.96x
Book Value / Share (Annual)$5.89
Price vs S&P 500 (13W)-43.12%
Beta1.42x
Revenue / Share (TTM)$0.00
ROE (TTM)-150.88%
52-Week Low$3.94
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-2.16est. -2.85
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.25
4.25
4.31
3.83
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PASGPassage Bio, Inc. Common Stock | — | — | D | $5.85 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Passage Bio develops genetic medicines for rare monogenic CNS disorders, including GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The company targets the underlying causes of these neurodegenerative conditions to address significant unmet medical needs.